Novartis’ Mayzent EU approval offers SPMS patients new optionNovartis’ Mayzent has been approved in Europe for adults with secondary progressive multiple sclerosis (SPMS) and active disease. Share XNovartis’ Mayzent EU approval offers SPMS patients new optionhttps://pharmaphorum.com/news/novartis-mayzent-eu-approval-offers-spms-patients-new-option/
Novartis strikes landmark deal with NHS to speed up inclisiran accessNovartis and NHS England have forged a pact to accelerate the access of its new cholesterol-lowering drug inclisiran Share XNovartis strikes landmark deal with NHS to speed up inclisiran accesshttps://pharmaphorum.com/news/novartis-strikes-landmark-deal-with-nhs-to-speed-up-inclisiran-access/
Ligelizumab could top Xolair in chronic hives, says NovartisNovartis’ immunoglobulin E inhibitor Xolair has been a mainstay of treatment for chronic spontaneous urticaria (CSU) for many Share XLigelizumab could top Xolair in chronic hives, says Novartishttps://pharmaphorum.com/news/ligelizumab-could-top-xolair-in-chronic-hives-says-novartis/
Novartis sets up free lottery for $2.1m SMA drug outside USNovartis is planning to give away 100 doses of its hugely expensive spinal muscular atrophy gene therapy Zolgensma Share XNovartis sets up free lottery for $2.1m SMA drug outside UShttps://pharmaphorum.com/news/novartis-to-give-away/
2019: the year of the pharma mega-merger2019 will be remembered as the year of the pharma mega-merger. Richard Staines looks back at a year Share X2019: the year of the pharma mega-mergerhttps://pharmaphorum.com/views-and-analysis/2019-the-year-of-the-pharma-mega-merger/
Novartis top of pile in European pharma in 2020, say Jefferies analystsJefferies’ team of analysts have recently been touting Roche as their favourite big European pharma – but going Share XNovartis top of pile in European pharma in 2020, say Jefferies analystshttps://pharmaphorum.com/news/novartis-top-of-pile-in-european-pharma-say-jefferies-analysts/
Novartis axes asthma drug fevipiprant after more trial woesIt’s nearly always bad news when pharma companies provide an “update” about a trial – and the statement Share XNovartis axes asthma drug fevipiprant after more trial woeshttps://pharmaphorum.com/news/novartis-axes-asthma-drug-fevipiprant-after-more-trial-woes/
Novartis’ blockbuster hope Beovu clears EMA advisory panelNovartis could launch its new age-related macular degeneration drug in Europe early next year after getting a green Share XNovartis’ blockbuster hope Beovu clears EMA advisory panelhttps://pharmaphorum.com/news/novartis-blockbuster-hope-beovu-clears-ema-advisory-panel/
Gilead to file new CAR-T, setting up potential mid-2020 launchGilead’s Kite unit plans to file its latest CAR-T therapy on the basis of a new study showing Share XGilead to file new CAR-T, setting up potential mid-2020 launchhttps://pharmaphorum.com/news/gilead-to-file-new-car-t/
